Dietary Supplement Adverse Event Report Data From the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS),2004-2013
Restricted accessResearch articleFirst published online May, 2018
Dietary Supplement Adverse Event Report Data From the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS),2004-2013
Background: The Food and Drug Administration (FDA)’s Center for Food Safety and Applied Nutrition (CFSAN) oversees the safety of the nation’s foods, dietary supplements, and cosmetic products. Objective: To present a descriptive analysis of the 2004-2013 dietary supplement adverse event report (AER) data from CAERS and evaluate the 2006 Dietary Supplements and Nonprescription Drug Consumer Protection Act as pertaining to dietary supplements adverse events reporting. Methods: We queried CAERS for data from the 2004-2013 AERs specifying at least 1 suspected dietary supplement product. We extracted the product name(s), the symptom(s) reported, age, sex, and serious adverse event outcomes. We examined time trends for mandatory and voluntary reporting and performed analysis using SAS v9.4 and R v3.3.0 software. Results: Of the total AERs (n = 15 430) received from January 1, 2004, through December 31, 2013, indicating at least 1 suspected dietary supplement product, 66.9% were mandatory, 32.2% were voluntary, and 0.9% were both mandatory and voluntary. Reported serious outcomes included death, life-threatening conditions, hospitalizations, congenital anomalies/birth defects and events requiring interventions to prevent permanent impairments (5.1%). The dietary supplement adverse event reporting rate in the United States was estimated at ~2% based on CAERS data. Conclusions: This study characterizes CAERS dietary supplement adverse event data for the 2004-2013 period and estimates a reporting rate of 2% for dietary supplement adverse events based on CAERS data. The findings show that the 2006 Dietary Supplements and Nonprescription Drug Consumer Protection Act had a substantial impact on the reporting of adverse events.
Dietary Supplements Health and Education Act of 1994. Pub L 103-417, 108 Stat 4325.
2.
WallaceTC. Twenty years of the Dietary Supplement Health and Education Act: how should dietary supplements be regulated. J Nutr. 2015;145:1683-1686.
3.
DenhamBE. Dietary supplements—regulatory issues and implications for public health. JAMA. 2011;306:428-429.
4.
SwannJP. The history of efforts to regulate dietary supplements in the USA. Drug Test Anal. 2016;8:271-282. doi:10.10023/dta.1919
5.
DickinsonA. History and overview of DSHEA. Fitoterapia. 2011;82:5-10.
6.
DodgeTLittDKaufmanA. Influence of the Dietary Supplement Health and Education Act on consumer beliefs about the safety and effectiveness of dietary supplements. J Health Commun. 2011;16:230-244.
7.
RapakaRSCoatesPM. Dietary supplements and related products: a brief summary. Life Sci. 2006;78:2026-2032.
8.
GardinerPSarmaDNLow DogTet al. The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiol Drug Saf. 2008;17:962-970.
Life Sciences Research Office. Recommendations for Adverse Event Monitoring Programs for Dietary Supplements. Bethesda, MD: Life Sciences Research Office; 2004.
11.
FrankosVHStreetDAO’NeillRK. FDA regulation of dietary supplements and requirements regarding adverse event reporting. Clin Pharmacol Ther. 2010;7:239-244. doi:10.1038/clpt.2009.263
12.
WallaceRBGryzlakBMZimmermanMBNislyNL. Application of FDA adverse event data to the surveillance of dietary botanical supplements. Ann Pharmacother. 2008;42:653-660.
13.
Dietary Supplements and Nonprescription Consumer Protection Act of 2006. Pub L 109-462. 109th Congress, December22, 2006
14.
KlontzKCDeBeckHJLeBlancPet al. The role of adverse event reporting in the FDA response to a multistate outbreak of liver disease associated with a dietary supplement. Public Health Rep. 2015;130:526-532.
15.
ShaderRIGreenblattDJ. MedWatch, the new FDA adverse effects reporting system. J Clin Psychopharmacol. 1993;13:303-304.
16.
KesslerDA. MedWatch: the new FDA medical products reporting program. Clin Pharm. 1993;12:529-532.
Food and Drug Administration (FDA), Center For Food Safety and Applied Nutrition (CFSAN), CFSAN Adverse Event Reporting (CAERS). CAERS Business Objects User Manual, Version 1.2. 2010.SAP User Group
19.
GellerAIShehabNWeidleNJet al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373:1531-1540.
20.
SAS Software, Version 9.3. Cary, NC: SAS Institute; 2011.
21.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. https://www.R-project.org/. Accessed November 9, 2017.
22.
KavaRMeisterKAWhelanEMLukachkoAMMirabileC. Dietary supplement safety information in magazines popular among older readers. J Health Commun. 2002;7:13-23.
23.
Kavaet al. Dietary supplement used and the potential for drug-supplement interaction among older Americans. Manuscript submitted for publication.
24.
AviganMIMozerskyRPSeeffLB. Scientific and regulatory perspective in herbal and dietary supplements associated hepatotoxicity in the United States. Int J Mol Sci. 2016;17:331. doi:10.3390/ijms17030331
25.
MillenAEDoddKWSubarAF. Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: the 1987, 1992, and 2000 National Health Interview Survey results. J Am Diet Assoc. 2004;104:942-950.
26.
WalkerA. The Relation Between Voluntary Notification and Material Risk in Dietary Supplements. FDA Commissioned Paper. FDA Docket 00N-1200(41). March9, 2000.
27.
Office of Inspector General Report: Adverse Event Reporting for Dietary Supplements. An Inadequate Safety Value. Washington, DC: Office of Inspector General; 2001.
28.
TollefsonL. Monitoring adverse reactions to food additives in the U.S. Food and Drug Administration. Regul Toxicol Pharmacol. 1988;8:438-446.
29.
Food and Drug Administration, HHS. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk: final rule. Fed Regist. 2004;69:6787-6854.
30.
United States Government Accountability Office. Dietary supplements. FDA may have opportunities to expand its use of reported health problems to oversee products. https://www.gao.gov/products/GAO-13-244. Accessed November 9, 2011.
31.
DuggiralaHJTonningJMSmithEet al. Use of data mining at the food and drug administration. J Am Med Inform Assoc. 2016;23:428-434. doi:10.1093/jamia/0cv063
32.
RosenthalSRobertC. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health. 1995;85:1706-1709.
33.
LobbA. Hepatotoxicity associated with weight-loss supplements: a case for better postmarketing surveillance. World J Gastroenterol. 2009;15:1786-1787.
34.
LitovitzTLKlein-SchwartzWRodgersGCJret al. 2001 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2002;20:391-452.
35.
DennehyCETsourounisCHornAJ. Dietary supplements related adverse events reported the California Poison Control System. Am J Health Syst Pharm. 2005;62:1476-1482.
36.
PalmerMEHallerCMcKinneyPEet al. Adverse events associated with dietary supplements: an observational study. Lancet. 2003;361:101-106.
